Can Keppra (levetiracetam) cause drowsiness at higher doses?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drowsiness with Higher Doses of Keppra (Levetiracetam)

Yes, Keppra (levetiracetam) can cause significant drowsiness at higher doses, with somnolence being one of the most common dose-dependent side effects reported in clinical studies.

Evidence for Drowsiness with Levetiracetam

The FDA drug label for levetiracetam explicitly lists somnolence as one of the primary adverse effects in cases of overdose 1. This drowsiness effect becomes more pronounced at higher doses:

  • Clinical studies show that somnolence and asthenia (weakness) increase in both frequency and severity with increasing doses of levetiracetam 2
  • At doses of 4000 mg per day, somnolence becomes more common, suggesting this may be the upper limit for some patients, though individual susceptibility varies 2

Dose-Response Relationship

The drowsiness effect of levetiracetam demonstrates a clear dose-response relationship:

  • In dose-escalation studies, somnolence was among the most commonly reported adverse effects, with frequency increasing at higher doses 3
  • In overdose cases, profound sedation and respiratory depression have been observed at concentrations 10-40 times higher than therapeutic levels 4

Clinical Implications

When prescribing levetiracetam, especially at higher doses, clinicians should:

  • Warn patients about potential drowsiness and advise against driving or operating machinery until they know how the medication affects them 1
  • Consider that individual susceptibility to somnolence varies significantly between patients 2
  • Be aware that drowsiness may be more pronounced during initial titration and may improve with continued use
  • Monitor for signs of excessive sedation, particularly when increasing the dose

Comparison with Other Medications

Unlike some other anticonvulsants, levetiracetam does not have significant interactions with other medications through liver cytochrome P450 pathways 1, which makes it a favorable option for many patients despite the potential for drowsiness.

Management of Drowsiness

If drowsiness becomes problematic:

  • Consider administering a larger portion of the daily dose at bedtime
  • Evaluate whether a lower dose might still provide adequate seizure control
  • Assess for other contributing factors (other medications, sleep disorders)
  • Do not abruptly discontinue levetiracetam as this may precipitate seizures

In severe cases of overdose with excessive drowsiness, supportive care is the primary management approach, as there is no specific antidote for levetiracetam overdose 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.